Measles Research Today is a free monthly online journal that collates and summarizes the latest research about Measles, including details on german measles, symptoms, vaccine, treatment, rubella.

Safety of a Two-Dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine Manufactured with Recombinant Human Albumin.

Rüger G, Gabutti G, Rümke H, Rombo L, Bernaola E, Diez-Domingo J, Martinon-Torres F, Høgh B, Konstantopoulos A, Fiquet A, Thomas S, Eymin C, Baudin M

1Kinder-Jugendarztpraxis, Wildeshausen, Germany; 2Università degli Studi di Ferrara, Ferrara, Italy; 3VAXINOSTICS, Rotterdam, The Netherlands; 4Center for Clinical Research, Sörmland County Council and Department of Medicine, Karolinska Institutet, Sweden; 5Hospital Virgen del Camino, Pamplona, Spain; 6Centro Superior de Investigación en Salud Pública, Valencia, Spain; 7Hospital Clínico Universitario de Santiago de Compostela and Vaccine Research Unit, Instituto de Investigación Sanitaria de Santiago, Santiago de Compostela, Spain; 8Hvidovre Hospital, University of Copenhagen, Denmark; 9Children's Hospital "Aglaia Kriakou", Athens, Greece; 10Sanofi Pasteur MSD, Lyon, France.

BACKGROUND:: ProQuad - a vaccine containing antigens from M-M-RVAXPRO (measles, mumps and rubella vaccine) and VARIVAX (varicella vaccine) - is indicated for simultaneous vaccination against measles, mumps, rubella and varicella (MMRV) in individuals from 12 months of age. To eliminate blood-derived products of human origin from the manufacturing process of the MMRV vaccine, recombinant human albumin (rHA) was selected as a replacement for human serum albumin (HSA). METHODS:: This open-label, multicentre clinical trial (clinicaltrials.gov identifier NCT00560755) was designed to describe the safety profile of a two-dose schedule of the MMRV vaccine at a 1-month interval in healthy children aged 12-22 months. RESULTS:: In total, 3,388 children received at least one dose of the MMRV vaccine. Overall, 3,376 (99.65%) children were included in the post-Dose 1 safety analysis, and 3,342 (98.64%) in the post-Dose 2 safety analysis. After Doses 1 and 2, the frequencies of children experiencing solicited injection-site reactions (Post-Dose 1: erythema 14.31%; swelling 5.57%; pain 10.31%; Post-Dose 2: erythema 30.46%; swelling 13.23%; pain 11.49%), rashes of interest (Post-Dose 1: 11.4%; Post-Dose 2: 2.78%), vaccine-related non-serious systemic adverse events (Post-Dose 1: 34.86; Post-Dose 2: 13.4%) and temperature ≥39.4°C (Post-Dose 1: 25.24%; Post-Dose 2: 12.06%) were consistent with those observed in previous studies of the MMRV vaccine manufactured with HSA. Neither serious allergic-type adverse events nor anaphylactic reactions were reported. CONCLUSION:: The results confirm the good safety profiles of MMRV and of MMR vaccines manufactured with rHA.

Published 9 July 2012 in Pediatr Infect Dis J.
Full-text of this article is available online (may require subscription).

Articles on Measles published 9 July 2012:

Development of monoclonal antibody-based immunoassays for detection of Helicobacter pylori neutrophil-activating protein.   J Immunol Methods.

Neutrophil-activating protein (NAP) is a major virulence factor expressed by Helicobacter pylori isolates associated with severe chronic gastroduodenal inflammation and peptic ulcers. NAP is one of the main protective antigens and a target for vaccine development against Helicobacter infection. In addition, NAP is a potent immune stimulator with potential application as a general vaccine adjuvant and in treatment of allergic diseases and cancer immunotherapy. NAP-specific immunoassays are ... [Abstract] [Full-text]

Response surface methodology to determine optimal measles-specific cytokine responses in human peripheral blood mononuclear cells.   J Immunol Methods, 382(1): 220-3.

Limitations of assay variability, labor costs, and availability of cells can affect the conduct of large population-based studies. The ability to determine optimal conditions for laboratory assessment of immune outcomes, including measurement of cytokines, can reduce the number of peripheral blood mononuclear cells (PBMCs) needed, reduce the labor costs involved, and the variability in secreted cytokine response by pooling cytokines from the same cell culture supernatant. Previously, we used ... [Abstract] [Full-text]

Immunogenicity, Immunologic Memory, and Safety Following Measles Revaccination in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy.   J Infect Dis.

Background. Response rates and immunologic memory following measles vaccination are reduced in human immunodeficiency virus (HIV)-infected children in the absence of highly active antiretroviral therapy (HAART).Methods. HIV-infected children 2 to <19 years old receiving HAART and with HIV loads <30 000 copies/mL, CD4% ≥15, and ≥1 prior measles-mumps-rubella vaccination (MMR) were given another MMR. Measles antibody concentrations before and 8, 32, and 80 weeks postvaccination ... [Abstract] [Full-text]

Articles on Measles published 4 July 2012:

Measles virus transmission from dendritic cell to T cells: formation of synapse-like interfaces concentrating viral and cellular components.   J Virol.

Transmission of measles virus (MV) to T cells by its early CD150+ target cells is considered as crucial for viral dissemination within the hematopoeitic compartment. Using co-cultures involving monocyte-derived dendritic cells (DC) and T cells, we now describe that T cells acquire MV most efficiently from cis-infected DCs rather than DCs having trapped MV (trans-infection). Transmission involves interactions of the viral glycoprotein H with its receptor CD150 and is therefore more efficient to ... [Abstract] [Full-text]

Articles on Measles published 3 July 2012:

Association of Parkinson's disease with infections and occupational exposure to possible vectors.   Mov Disord.

The ultimate causes of idiopathic Parkinson's disease (PD) are not fully known, but environmental and occupational causes are suspected. Postencephalitic parkinsonism has been linked to influenza, and other viral infections have also been suspected to relate to PD. We estimated the relationship between PD and both infections and possible vectors of infection (i.e., animal and human) in a population-based, case-control study in British Columbia, Canada. We recruited 403 cases detected by their ... [Abstract] [Full-text]

Early vaccinations are not risk factors for celiac disease.   Pediatrics, 130(1): e63-70.

[Abstract] [Full-text]

Articles on Measles published 28 June 2012:

Toxicogenomic profiles in relation to maternal immunotoxic exposure and immune functionality in newborns.   Toxicol Sci.

A crucial period for the development of the immune system occurs in utero. This results in a high fetal vulnerability to immunotoxic exposure, and indeed, immunotoxic effects have been reported, demonstrating negative effects on immune related health outcomes and immune functionality. Within the NewGeneris cohort BraMat, a sub-cohort of the Norwegian Mother and Child Cohort Study (MoBa), immunotoxicity was demonstrated for polychlorinated biphenyls (PCB) and dioxins, showing associations ... [Abstract] [Full-text]

It's a long, long walk: accessibility to hospitals, maternity and integrated health centers in Niger.   Int J Health Geogr, 11(1): 24.

ABSTRACT: BACKGROUND: Ease of access to health care is of great importance in any country but particularly in countries such as Niger where restricted access can put people at risk of mortality from diseases such as measles, meningitis, polio, pneumonia and malaria. This paper analyzes the physical access of populations to health facilities within Niger with an emphasis on the effect of seasonal conditions and the implications of these conditions in terms of availability of adequate health ... [Abstract] [Full-text]

© 2004-2012 Measles Research Today. All Rights Reserved.